DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
11,100
Employees11,100
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
11,100
Employees11,100

DXCM Key Statistics

Market cap
29.57B
Market cap29.57B
Price-Earnings ratio
31.16
Price-Earnings ratio31.16
Dividend yield
Dividend yield
Average volume
5.88M
Average volume5.88M
High today
$78.52
High today$78.52
Low today
$73.00
Low today$73.00
Open price
$73.62
Open price$73.62
Volume
7.57M
Volume7.57M
52 Week high
$89.98
52 Week high$89.98
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

As of today, DexCom(DXCM) shares are valued at $75.00. The company's market cap stands at 29.57B, with a P/E ratio of 31.16.

As of 2026-06-09, DexCom(DXCM) stock has fluctuated between $73.00 and $78.52. The current price stands at $75.00, placing the stock +2.7% above today's low and -4.5% off the high.

The DexCom(DXCM)'s current trading volume is 7.57M, compared to an average daily volume of 5.88M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $89.98 and a 52-week low of $54.11.

In the last year, DexCom(DXCM) shares hit a 52-week high of $89.98 and a 52-week low of $54.11.

DXCM News

TipRanks 10h
DexCom price target raised to $91 from $81 at Raymond James

Raymond James raised the firm’s price target on DexCom (DXCM) to $91 from $81 and keeps a Strong Buy rating on the shares. While acknowledging the high expectat...

Benzinga 11h
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

DexCom Inc. (NASDAQ:DXCM) stock is trading higher on Monday after the diabetes management company reported positive results from its CONNECT randomized controll...

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes
TipRanks 1d
DexCom announces results from CONNECT trial of Dexcom G7

DexCom (DXCM) announced results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significa...

Analyst ratings

84%

of 31 ratings
Buy
83.9%
Hold
16.1%
Sell
0%

More DXCM News

Nasdaq 5d
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

Key Points DexCom is a leading innovator in the continuous glucose monitoring market with a global footprint across 52 countries. Insulet dominates the tubele...

DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.